Status: Recruiting
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Jun 3, 2026Locations: 1
Eligibility criteria
Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or... [+16]
Pure well-differentiated liposarcoma or low grade leiomyosarcoma. [+56]